Company Overview and News


Add PIX
to your dashboard

Headline News

BRIEF-‍Pixium Vision establishes an equity line financing with Kepler Cheuvreux​

2017-10-23 reuters
* ‍SHARES REPRESENT AN ISSUED CAPITAL OF EUR 6.2 M​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Pixium Vision Announces Updates On Its Epi-Retinal IRISII Bionic Vision System

2017-09-27 devicespace
Pixium Vision (FR0011950641 - PIX) (Paris:PIX), a company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, today announces updates on its epi-retinal IRIS®II system, CE marked for outer retinal degeneration, including Retinitis Pigmentosa.

Pixium Vision Announces H1 2017 Financial Results And Provides An Update On Its Activities

2017-07-27 devicespace
Pixium Vision (Paris:PIX) (FR0011950641 - PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, announces its financial results for the first half of 2017, approved July 26, 2017 by the Board of Directors. The Half-Year Financial Report is available on the Company's website.

Mainstay Medical Publishes 2016 Full Year Results and Business Update

2017-03-23 londonstockexchange
Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable restorative neurostimulation system to treat people with disabling Chronic Low Back Pain (“CLBP”), announces today the publication of its 2016 Annual Report.

Pixium Vision Announces First Implantation And Activation Of IRIS II In Spain

2017-02-16 devicespace
“The patient’s system was activated and he reported first perception of light. Per clinical protocol, the patient will now enter training and re-education which is supposed to help with the necessary learning how to interpret these new light signals.”

Pixium Vision Receives NUB Innovation Reimbursement Status-1 For 150 Electrode IRISII Bionic System In Germany

2017-02-14 devicespace
Pixium Vision (Paris:PIX), a company developing innovative bionic vision systems with the intention to allow patients who have lost their sight to lead more independent lives, today announced that the German Institute for the Hospital Remuneration System (InEK) has granted NUB (Neue Untersuchungs- und Behandlungsmethoden) Status-1 for IRIS®II, Pixium Vision’s first bionic vision system, equipped with a bio-inspired camera and a 150 electrodes epi-retinal implant with a proprietary design intended to be explantable and upgradable.

Pixium Vision Achieves Implantation Of 10 Patients In Its Clinical Trial With Its Innovative 150 Electrodes IRIS II Bionic Vision System

2017-01-12 devicespace
Pixium Vision (Paris:PIX), a company developing and commercializing innovative bionic vision systems with the intention to allow patients who have lost their sight to lead more independent lives, announces completion of 10 implants in its IRIS® II study. All implanted patients will now follow their re-education program as defined in the ongoing European multi-centric study for IRIS® II which was launched in January 2016.

Pixium Vision Release: Company Achieves Implantation Of 10 Patients In Its Clinical Trial With Its Innovative 150 Electrodes IRIS II Bionic Vision System

2017-01-11 devicespace
Pixium Vision (Paris:PIX), a company developing and commercializing innovative bionic vision systems with the intention to allow patients who have lost their sight to lead more independent lives, announces completion of 10 implants in its IRIS® II study. All implanted patients will now follow their re-education program as defined in the ongoing European multi-centric study for IRIS® II which was launched in January 2016.

Pixium Vision Announces The First Successful Implantation And Activation Of IRIS II, 150 Electrode Bionic Vision System, In The UK

2016-11-07 devicespace
World renowned Moorfields Eye Hospital in London implanted the first patient with IRIS® II, a bionic vision system equipped with a bio-inspired camera and a 150 electrode epi-retinal implant that is designed to be explantable.

CureVac Appoints As Chief Financial Officer

2016-10-11 devicespace
TUBINGEN, Germany, Oct. 11, 2016 /PRNewswire/ -- CureVac AG, the most clinically advanced mRNA company, today announced the appointment of Pierre Kemula as Chief Financial Officer (CFO). Mr. Kemula will join CureVac's management board and will be responsible for leading the company's financial and capital markets activities.

CureVac Appoints Pierre Kemula as Chief Financial Officer

2016-10-11 prnewswire
TUBINGEN, Germany, Oct. 11, 2016 /PRNewswire/ -- CureVac AG, the most clinically advanced mRNA company, today announced the appointment of Pierre Kemula as Chief Financial Officer (CFO). Mr. Kemula will join CureVac's management board and will be responsible for leading the company's financial and capital markets activities.

Pixium Sees A Bright Future In Europe

2016-07-26 seekingalpha
Pixium Vision is a distant second to market with its Iris II retinal implant for retinitis pigmentosa: Second Sight’s (NASDAQ:EYES) Argus II has been available in Europe since 2011. But with more than twice as many electrodes the Iris II could permit patients better vision than the competing device.

Pixium Vision Receives Clinical Trial Approval From For 150 Electrode IRISII Bionic Vision System

2016-05-31 devicespace
World renowned Moorfields Eye Hospital joins the clinical trial for IRIS® II, a bionic vision system equipped with a bio-inspired camera and a 150 electrode epi-retinal implant with an explantable design